Jie Wang

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4.1K citations

Medicine, Oncology, Pharmacology +10

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Zhijie Wang, Jianchun Duan, Shangli Cai et al. · JAMA Oncology · 2019 · 495 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Shugeng Gao, Ning Li, Shun‐Yu Gao et al. · Journal of Thoracic Oncology · 2020 · 415 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa et al. · The Lancet Oncology · 2015 · 410 citations

Medicine, Oncology, Pharmacology +15

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

Jie Wang, Shun Lü, Xinmin Yu et al. · JAMA Oncology · 2021 · 398 citations · Full text

Medicine, Oncology, Pharmacology +16